1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Switzerland Pharmaceuticals and Healthcare Report Q4 2016

Switzerland Pharmaceuticals and Healthcare Report Q4 2016

  • September 2016
  • -
  • Business Monitor International
  • -
  • 76 pages

Includes 3 FREE quarterly updates

BMI View:

Switzerland will remain amongst the wealthiest countries in the world in real GDP per capitaterms, which together with an aging population and a preference for patented medicines, will keeppharmaceutical spending high. However, faced with growing healthcare costs, the Swiss government will tocontinue to enforce measures that restrict growth in medicine sales - including the roll-out of initiatives thatenforce the cost effective pricing and rational prescribing of medicines.

Headline Expenditure Projections

- Pharmaceuticals: CHF7.07bn (USD7.34bn) in 2015 to CHF7.08bn (USD6.89bn) in 2016; +0.25% inlocal currency terms and -6.1% in US dollar terms.

- Healthcare: CHF73.68bn (USD76.55bn) in 2015 to CHF75.45bn (USD73.39bn) in 2016; +2.4% growthin local currency terms and -4.1% in US dollar terms.Risk/Reward IndexSwitzerland's Pharmaceutical Risk/Reward Index score for Q416 stands at 73.1 out of a total of 100, abovethe regional average of 70.6. High per-capita spending on medicines, as well as a growing demand formedicines as a result of the country's ageing population, makes Switzerland an attractive market in which tolaunch innovative medicines. However, the government's focus on cost containment within thepharmaceuticals and healthcare sector will continue to pose challenges to drug companies.Latest Updates

- In 2015, in volume terms, 58% of all medicine packs sold in Switzerland were reimbursable,experiencing a 2.9% increase over 2014 volumes.

- In 2015, sales of medicines for the treatment of the central nervous system accounted for the largestmarket share at 14.5%.

- In 2015, the 24 Interpharma companies spent more than CHF6.9bn in research and development (R&D)in Switzerland.

Table Of Contents

Switzerland Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (2013-2019) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Switzerland 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Switzerland 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Switzerland 2012-2020) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Switzerland 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Switzerland 2012-2020) 19
Patented Drug Market Forecast 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Switzerland 2012-2020) 21
Generic Drug Market Forecast 22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Switzerland 2012-2020) 23
OTC Medicines Market Forecast 24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Switzerland 2012-2020) 25
Pharmaceutical Trade Forecast 26
Table: Pharmaceutical Trade Data And Forecasts (Switzerland 2014-2020) 27
Table: Pharmaceutical Trade Data And Forecasts local currency (Switzerland 2014-2020) 27
Industry Risk/Reward Index 28
Western Europe Risk/Reward Index 28
Switzerland Risk/Reward Index 34
Rewards 34
Risks 34
Regulatory Review 36
Intellectual Property Issues 36
Pricing Regime 36
Reimbursement Regime 37
Market Overview 39
Healthcare Sector 40
Table: 2013 and 2014: Health Insurance Premiums 42
Table: Healthcare Resources (Switzerland 2010-2015) 44
Table: Healthcare Personnel (Switzerland 2010-2015) 45
Table: Healthcare Activity (Switzerland 2010-2015) 46
Research and Development 46
Clinical Trials 47
Epidemiology 48
Competitive Landscape 51
Research-Based Industry 51
Table: Multinational Market Activity 52
Generic Drugmakers 53
Pharmaceutical Retail Sector 53
Company Profile 54
GlaxoSmithKline 54
Novartis 56
Roche 61
Demographic Forecast 65
Table: Population Headline Indicators (Switzerland 1990-2025) 66
Table: Key Population Ratios (Switzerland 1990-2025) 66
Table: Urban/Rural Population and Life Expectancy (Switzerland 1990-2025) 67
Table: Population By Age Group (Switzerland 1990-2025) 67
Table: Population By Age Group % (Switzerland 1990-2025) 68
Glossary 70
Methodology 72
Pharmaceutical Expenditure Forecast Model 72
Healthcare Expenditure Forecast Model 72
Notes On Methodology 73
Risk/Reward Index Methodology 74
Index Overview 75
Table: Pharmaceutical Risk/Reward Index Indicators 75
Indicator Weightings 76

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.